United Therapeutics: The $4 Billion Run-Rate Promise Meets a Flat Line
Revenue stalls near $780–800M, guidance is shelved, and the bull case now rests entirely on 2027 IPF and ralinepag launches — the stock is down 14% from its May peak.
UTHR · Earnings Call · 2026-08-05
The flat line
For five consecutive quarters, United Therapeutics' revenue has been stuck in a $780–800M range. Q2 2026 came in at $783M, essentially flat with Q1 and roughly 2% below the prior-year quarter. The tone of the call reflects it. COO Michael Benkowitz acknowledged the miss head-on: “While these results were below our expectations, they do not change our confidence in the strength of our business, the opportunities in front of us or our ability to create substantial value over the coming years.” — Michael Benkowitz, Chief Financial Officer · 2026-08-05 The more consequential sentence followed seconds later: “we are not reaffirming or updating any prior revenue growth expectations for 2026 today.” — Michael Benkowitz, Chief Financial Officer · 2026-08-05 For a company that had spent a year pitching double-digit growth and a $4B annualized run rate by the end of 2027, pulling the guidance marks a genuine pivot in management posture. The source of the pressure is explicit: Nebulized Tyvaso is losing ground. Benkowitz said the product "remained pressured by competitive dynamics within the inhaled prostacyclin category as patients and providers evaluate an increasing number of treatment options." That is a stark departure from prior quarters. Six months earlier, in the Q4 2025 call, he had insisted there was “really no material impact from the launch of YUTREPIA” — Michael Benkowitz, Chief Commercial Officer or similar leadership role in commercialization · 2025-10-29 and that it "really kind of grows the pie of the addressable patient population." By this quarter, the competitor is no longer growing the pie — it is eating into the neb franchise. The fundamentals confirm the stall. Total revenue flatlined: $799M (Q2'25), $800M (Q3'25), $790M (Q4'25), $794M (Q1'25), $782M (Q1'26) — the top line simply stopped inflecting. Meanwhile gross margin fell to 82.9%, down 5.4 points year-over-year, evidence that what growth remains is coming at the expense of profitability.The next two bets: IPF and ralinepag
The counterweight is the pipeline, and this quarter delivered what management frames as its two most consequential filings. Martine Rothblatt: “we recently submitted to the FDA what we believe are two of the most important new drug applications in rare pulmonary disease: the sNDA for nebulized Tyvaso in IPF and the NDA for ralinepag in PAH.” — Martine Rothblatt, Chief Executive Officer · 2026-08-05 This is the core of the new narrative: Tyvaso in IPF and ralinepag in PAH as separate multibillion-dollar opportunities. The phrase "super prostacyclin" — the innovation flashpoint of prior calls — has actually dropped off this quarter's top-keyword list, replaced by launch-oriented language like commercial performance and "launch trajectory." The regulatory overhang is priority review: Leigh Peterson told the Street the sNDA was filed "late June," with a six-month review if priority is granted and ten months otherwise. The headline ambition still stands, but with a notable hedge. Benkowitz:Six months ago, at the February call, the same run rate was pitched as attainable from the existing portfolio alone — Martine had said it "does not require the contribution of these three new product launches" (“It does not require the contribution of these three new product launches” — Martine Rothblatt, Chief Executive Officer or similar top executive · 2026-02-25). Now it requires the launches. That shift — from organic growth to launch-dependent growth — is the single biggest change in the investment thesis.We have previously projected a $4 billion revenue run rate by the end of 2027 with our existing commercial portfolio. We still see a path to achieve this, although it has certainly narrowed. Factoring in some of the revenue from our anticipated IPF and ralinepag launches next year should get us there and beyond.
LTFI: the culture as a defense
The most revealing moment was the introduction of a new rallying cry, LTFI — "Lock The F In." Benkowitz explained it as cultural insurance against complacency:It is a telling addition. When a management team introduces an accountability slogan, it usually means the sell side stopped believing the prior narrative. The keyword trajectory backs that up: this quarter's sales force surged to #2 (the team was doubled and deployed July 1), while "Stealth mode," "computational biology," and "super prostacyclin" — the innovation flashwords of 2025 — have all but vanished from the conversation. What remains unresolved is whether the market will be patient. The stock trades at 7.9x price-to-revenue, up ~70% year-over-year on flat revenue — a multiple that presumes the IPF and ralinepag launches land as planned. The tape shows the doubt: UTHR is down about 10% over the last 90 days and sits 14% below its May 6 peak near $597, the date Q1 results hit with TETON-1 in tow. The balance sheet gives management room to wait, though: effective net cash stands at $9.0B, and the company stepped up to a $1.5B share repurchase in Q1 2026 after years of minimal buybacks. For now, the message is one of trust in transition: the flat line is a bridge, not a destination. But with guidance officially shelved, the burden of proof has shifted entirely to 2027.LTFI is our commitment to all of those stakeholders. It's a reminder that, while we are excited about what may come next, our focus remains on what we must deliver now.